Adding Actelion's portfolio to our already strong
Janssen Pharmaceuticals business is a unique opportunity for us to expand our portfolio with leading, differentiated in - market medicines and promising late - stage products.
In 2001, he was appointed president of
Janssen Pharmaceutical Inc., and in 2003 he was named company group chairman of the Johnson & Johnson
pharmaceutical business in Europe, the Middle East and Africa.